Interview: Ellson Chen, President & CEO, Vita Genomics, Taiwan
The President & CEO of Vita Genomics talks about the advantages that genomic testing offer both to sick and healthy patients, as well as the opportunities to catalogue the science…
Address: 7 Fl., No. 6, Sec. 1, Jung-Shing Road, Wugu Shiang, Taipei, Taiwan
Tel: (+886) 2-8976-9123
Web: http://www.vitagenomics.com/
Vita Genomics, founded in March 2001, has established its headquarter in Taiwan, a marketing office in California, USA, and a wholly owned subsidiary GeneCore in Shanghai, China. Vita Genomics has envisioned itself to be an important player in the healthcare industry by offering advanced and targeted molecular diagnostic products and services, providing more efficient and safer medical solutions, improving the drug development process, and lowering the overall healthcare cost through the pharmacogenomics approaches.Vita Genomics has already built up strong relationships with research institutions and medical organizations throughout Taiwan and China. We are constantly looking for pharmaceutical partners who can benefit from identifying patients for drug responsiveness prior to treatments, partners who would fund expanded pharmacogenomics studies that will enable us to validate the responsiveness of all significant genotypes, and partners who would co-develop DNA-based molecular diagnostic products. Vita Genomics is an active participant in modernizing Taiwan healthcare system. We are establishing the infrastructure needed to add the molecular profile information to the healthcare integrated circuit (IC) card. This is a first step in creating personalized medicine in the future. In addition, Vita Genomics can act as the conduit between the western world and China because we have already established a beachhead in Shanghai.
Vita Genomics follows the high standards of US FDA guidelines in collecting samples in conducting research and clinical studies.Vita Genomics concentrates on the elucidation of the genes and pathways involved in various diseases and on the drug responsiveness of patients in an attempt to improve the healthcare system.
The President & CEO of Vita Genomics talks about the advantages that genomic testing offer both to sick and healthy patients, as well as the opportunities to catalogue the science…
Kao Su-Chin Chang, founder and chairman of Weidar Chemical and Pharmaceutical, describes the robust development and international expansion of this historical domestic pharmaceutical manufacturer and the company’s enduring commitment to…
Lawrence Gan, President and CEO of Taiwan’s Development Center for Biotechnology (DCB) explains his vision and strategy to enhance DCB’s R&D expertise by adopting some of the best practices of…
Thomas Yuan, the CEO of TFBS Bioscience, documents the tailored added-value that this fast-growing product testing company strives to bring to emerging pharmaceutical and biotech companies in the Asia Pacific…
Grace Yeh, Founder, President, and CEO of PharmaEngine, one of the most eye-catching success stories to recently emerge from Taiwan’s maturing biopharmaceutical sector, documents the main success factors that have…
Du-Shieng Chien, President & CEO of TaiRx, a Taiwan-based biopharmaceutical company focused on unmet medical needs, provides insights into the recent development of CVM 1118, a revolutionary cancer treatment targeting…
Signed in June 2010, the Economic Cooperation Framework Agreement (ECFA) between Taiwan and China was set to reduce tariffs and commercial barriers between the two countries. Obviously, such a deal…
In the second part of this two-part interview, the chairman of TTY looks back at his experiences in the Taiwanese market, and assess what could have been done differently with…
In Taiwan, biotech is finally booming, and more and more of the companies benefitting from this boom are listing on the Gre Tai Securities Market (GTSM), built with small to…
The past three years have been some of the most eventful in memory for Taiwan’s life sciences industry. At this year’s Bio Taiwan exhibition, the annual conference that invites…
The Chairman and CSO of TCM Biotech offer perspectives on the potential of botanical drugs, and chart their biotech company’s trajectory in bringing these drugs to both the Chinese and…
The president of Adimmune Corporation discusses how the avian flu outbreak of 2006/2007 changed the course of the drug manufacturing industry in Taiwan, what that meant for Adimmune, and how…
The minister in charge of medical tourism in Taiwan speaks about the country’s advantages over its Asian neighbours, and how the new era of Taiwan’s medical services will…
See our Cookie Privacy Policy Here